Wednesday, June 23, 2021
ADVT 
National

Health Canada approves Johnson & Johnson vaccine

Darpan News Desk The Canadian Press, 05 Mar, 2021 06:23 PM
  • Health Canada approves Johnson & Johnson vaccine

The addition of another COVID-19 vaccine to Canada's arsenal and accelerated deliveries for another had government officials taking an optimistic tone Friday about the path of the pandemic in Canada.

Health Canada announced the approval of the COVID-19 vaccine from Johnson & Johnson, saying regulators have evidence showing the vaccine is both safe and effective against the novel coronavirus that causes the disease.

Meanwhile, Prime Minister Justin Trudeau also said Canada will get 1.5 million more doses of Pfizer-BioNTech's COVID-19 vaccine delivered this month, and another two million doses that were set to arrive in the summer will now come in April and May. "We are expecting far more doses by September than there are Canadians, even given that we're only talking about doses from four different approved companies right now," Trudeau said Friday.

"We have reasons to be optimistic." The approval of the Johnson & Johnson vaccine could markedly change the pace of vaccinations in Canada. It only requires a single dose and can be stored and transported at refrigerated temperatures for at least three months, facilitating distribution across the country.

There is no timeline yet for its delivery, with those details still being hammered out, federal procurement minister Anita Anand said.

Canada has pre-purchased 10 million doses of the Johnson & Johnson vaccine, developed by subsidiary Janssen Pharmaceuticals. Those are to be delivered by the end of September. Canada has options to buy another 28 million doses. Health Canada has now approved four distinct COVID-19 vaccines, with the others being from Pfizer-BioNTech, Moderna and Oxford-AstaZeneca. The regulator includes a fifth on its list of authorized shots: Covishield, which is a separate brand name for doses of the Oxford-AstraZeneca vaccine produced at the Serum Institute of India.

Apart from the Johnson & Johnson vaccine, they all require two shots spaced weeks or months apart.

All have varying levels of efficacy and are being allocated in part based on what ages they are approved for and their differing shipping and storage requirements.

The National Advisory Committee on Immunization is in charge of helping shape the guidelines around who gets what and when, taking into account not just scientific information but demographic factors, supply and capacity for the provinces to deliver. The J&J vaccine has been approved for use in adults and clinical trials are underway to see if it will be safe for children, Dr. Supriya Sharma, the chief medical adviser at Health Canada, said Friday.

Clinical trials are also underway on the other vaccines to see how safe they are for kids, but Sharma suggested it will still be months yet before they will be able to get shots.

"Potentially, by the end of the calendar year, we might have some answers for children," she said. In clinical trials, the J&J vaccine was shown to be 66 per cent effective overall in preventing moderate to severe COVID-19, and was also shown to provide protection against some of the variants of the virus currently in circulation.

Sharma stressed no matter which vaccines Canadians get, they will help protect people from getting COVID-19, as well as becoming seriously ill.

"What's really important is whether any of the vaccines will prevent you from being hospitalized, or dying of COVID-19. We know that all of the vaccines will protect you." The news from Pfizer that it will speed up deliveries comes after a marked delay in the national vaccination effort in January and February, when the company decided to upgrade production lines at a major factory in Belgium. Production problems also slowed the initial rollout of the Johnson & Johnson vaccine in the U.S. after that country approved it in February. Americans were to get 10 million doses as soon as the vaccine was approved but only four million doses shipped had been shipped by March 1.

The U.S. expects to get another 16 million doses by the end of March and 100 million total by the end of June.

There remains only one more vaccine currently under review by Health Canada, called Novavax, and Sharma said a decision on whether it can be used in Canada is weeks or maybe even months away.

MORE National ARTICLES

B.C. expands small business recovery grant program

B.C. expands small business recovery grant program

The province has also extended the deadline for businesses to apply from the end of this month to Aug. 31, or until all the money has been spent.

B.C. expands small business recovery grant program

Vaccine efficacy is being misinterpreted: experts

Vaccine efficacy is being misinterpreted: experts

Many of those who did become infected after getting a vaccine in the trials experienced mild illness, according to the data, which Chakrabarti says isn't a big concern.

Vaccine efficacy is being misinterpreted: experts

East Van intersection re-opened following 24 hour blockade

East Van intersection re-opened following 24 hour blockade

Four people were arrested by Vancouver Police after refusing repeated requests to clear the intersection – a main entrance to the Port of Vancouver and a major intersection in the city.

East Van intersection re-opened following 24 hour blockade

Copper deadly to bacteria, study shows

Copper deadly to bacteria, study shows

As part of its response to the COVID-19 pandemic, TransLink was the first transit agency in North America to test copper on high-touch surfaces.

Copper deadly to bacteria, study shows

Fourth vaccine approval expected in days

Fourth vaccine approval expected in days

If that happens it will add a fourth option to Canada's efforts to immunize our way to an end to the pandemic and the first to require only one dose.

Fourth vaccine approval expected in days

Premiers put pre-budget pressure on Ottawa

Premiers put pre-budget pressure on Ottawa

They argue the federal government shoulders only 22 per cent of the cost of health care; their demand would increase that share to 35 per cent.

Premiers put pre-budget pressure on Ottawa